US2011070609A1PendingUtilityA1

Production of Foreign Nucleic Acids and Polypeptides in Sprout Systems

44
Assignee: IBIO INCPriority: Nov 12, 2002Filed: Apr 5, 2010Published: Mar 24, 2011
Est. expiryNov 12, 2022(expired)· nominal 20-yr term from priority
C12N 15/8257C12N 15/8203C07K 14/32A61K 36/31C12N 15/8258C07K 14/61C12N 9/88C12N 9/16A61K 38/00A61K 2039/542
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides systems and methods for producing a nucleic acid or protein in transgenic sprouted seedlings or sprouted seedlings engineered to transiently express a nucleic acid or protein of interest. The sprouted seedlings of the invention are grown in a contained, regulatable environment, wherein expression of a pharmaceutically active protein is controlled by an exogenously inducible promoter or a viral promoter. The sprouted seedlings may be eaten live or preferably harvested live to preserve the maximal biological activity of the nucleic acid or protein.

Claims

exact text as granted — not AI-modified
1 . A method for producing pharmaceutically active protein in sprouted seedlings, comprising the steps of:
 infusing a sprouted seedling with a viral expression cassette encoding a pharmaceutically active protein and additional virus encoding proteins, wherein a viral promoter drives expression of a nucleic acid encoding the pharmaceutically active protein; and   growing the sprouted seedlings in a contained, regulatable environment;   wherein growing the sprouted seedlings allows for production of the nucleic acid encoding the pharmaceutically active protein, resulting in production of pharmaceutically active protein produced in the sprouted seedling.   
     
     
         2 . The method of  claim 1 , further comprising the step of homogenizing live sprouted seedlings expressing the pharmaceutically active protein in the presence of a homogenization buffer. 
     
     
         3 . The method of  claim 1 , further comprising purifying the pharmaceutically active protein from the homogenization buffer. 
     
     
         4 . The method of  claim 1 , wherein the sprouted seedling is an edible sprouted seedling. 
     
     
         5 . The method of  claim 1 , wherein the sprouted seedling is of the  Brassica  species. 
     
     
         6 . The method of  claim 5 , wherein the  Brassica  species is selected from the group consisting of  Brassica napus, Brassica rapa,  and  Brassica juncea.    
     
     
         7 . The method of  claim 1 , wherein the sprouted seedling is of a plant selected from the group consisting of alfalfa, radish, mustard, mung bean, broccoli, watercress, soybean, wheat sunflower, cabbage, clover, and lentil. 
     
     
         8 . The method of  claim 1 , wherein the contained, regulatable environment comprises a housing unit with climate control. 
     
     
         9 . The method of  claim 8 , wherein the climate control comprises controlling any of the group selected from the temperature, the humidity, the lighting, the water delivery, the nutrient delivery, and the amount of gas delivery of the housing unit. 
     
     
         10 . The method of  claim 1 , wherein the pharmaceutically active protein is selected from the group consisting of antigens, antibodies, enzymes, receptors, hormones, growth factors, growth factor receptors, cytokines and immune system proteins, binding proteins, transcription and translation factors, oncoprotiens or proto-oncoprotiens, muscle proteins, myeloproteins, neuroactive proteins, tumor growth suppressing proteins, anti-sepsis proteins, structural proteins, and blood proteins. 
     
     
         11 . A method for producing a pharmaceutically active protein in sprouted seedlings, comprising the steps of:
 infusing a sprouted seedling with  Agrobacterium  comprising a viral expression cassette encoding a pharmaceutically active protein and additional virus encoding proteins, wherein a viral promoter drives expression of a nucleic acid encoding the pharmaceutically active protein; and   growing the sprouted seedlings in a contained, regulatable environment;   wherein growing the sprouted seedlings allows for production of the nucleic acid encoding the pharmaceutically active protein, resulting in production of pharmaceutically active protein produced in the sprouted seedling.   
     
     
         12 . The method of  claim 11 , further comprising the step of homogenizing live sprouted seedlings expressing the nucleic acid or protein in the presence of a homogenization buffer. 
     
     
         13 . The method of  claim 12 , further comprising purifying the nucleic acid or protein from the homogenization buffer. 
     
     
         14 . The method of  claim 1 , wherein the sprouted seedling is an edible sprouted seedling. 
     
     
         15 . The method of  claim 1 , wherein the sprouted seedling is of the Brassica genus. 
     
     
         16 . The method of  claim 15 , wherein the  Brassica  species is selected from the group consisting of  Brassica napus, Brassica rapa,  and  Brassica juncea.    
     
     
         17 . The method of  claim 1 , wherein the sprouted seedling is of a plant selected from the group consisting of alfalfa, radish, mustard, mung bean, broccoli, watercress, soybean, wheat sunflower, cabbage, clover, and lentil. 
     
     
         18 . The method of  claim 1 , wherein the contained, regulatable environment comprises a housing unit with climate control. 
     
     
         19 . The method of  claim 18 , wherein the climate control comprises controlling any of the group selected from the temperature, the humidity, the lighting, the water delivery, the nutrient delivery, and the amount of gas delivery of the housing unit. 
     
     
         20 . The method of  claim 11 , wherein the nucleic acid or protein is selected from the group consisting of antigens, antibodies, enzymes, receptors, hormones, growth factors, growth factor receptors, cytokines and immune system proteins, binding proteins, transcription and translation factors, oncoprotiens or proto-oncoprotiens, muscle proteins, myeloproteins, neuroactive proteins, tumor growth suppressing proteins, anti-sepsis proteins, structural proteins, and blood proteins.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.